Barclays PLC Boosts Stock Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Barclays PLC raised its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 24.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,674 shares of the company’s stock after purchasing an additional 1,109 shares during the quarter. Barclays PLC’s holdings in ClearPoint Neuro were worth $64,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Renaissance Technologies LLC grew its position in ClearPoint Neuro by 562.6% in the 2nd quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock valued at $915,000 after buying an additional 144,088 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of ClearPoint Neuro by 11.6% in the second quarter. XTX Topco Ltd now owns 13,010 shares of the company’s stock valued at $70,000 after acquiring an additional 1,353 shares in the last quarter. Marshall Wace LLP increased its stake in shares of ClearPoint Neuro by 202.2% during the second quarter. Marshall Wace LLP now owns 58,260 shares of the company’s stock worth $314,000 after acquiring an additional 38,984 shares during the period. Point72 DIFC Ltd acquired a new position in shares of ClearPoint Neuro during the second quarter worth about $32,000. Finally, Cubist Systematic Strategies LLC purchased a new position in ClearPoint Neuro during the second quarter worth about $419,000. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Trading Down 2.4 %

Shares of CLPT opened at $15.07 on Friday. The stock’s 50 day moving average is $13.72 and its two-hundred day moving average is $11.28. ClearPoint Neuro, Inc. has a twelve month low of $5.11 and a twelve month high of $17.47. The firm has a market capitalization of $415.71 million, a PE ratio of -21.84 and a beta of 1.01.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.